On March 27th, the signing ceremony for the settlement of Mabgeek Biotech in WORLO COMPUTING-CHANGSH
Learn moreChime Biologics and Mabgeek Achieve MG-K10 PPQ Milestone, Advancing Atopic Dermatitis and Asthma The
Learn moreRecently, the innovative monoclonal antibody drug "MG-K10 Humanized Monoclonal Antibody Injection" s
Learn moreRecently, Hunan Mabgeek Biotech Co., Ltd. (hereinafter referred to as "Mabgeek Biotech"), a leading
Learn moreSwipe to see more pictures The instructor kicked off the seminar with a unique interactive game. In a relaxed and pleasant atmosphere, members discussed the theme of "From Excellence to Excellence",
Learn moreOn March 11, 2024, Mabgeek Biotech announced that it will present the top-line data of the Phase II
Learn moreOn December 13, 2023, Mabgeek Biotech has obtained the clinical approval for a drug for sinusitis. submitted the innovative monoclonal antibody drug "MG-K10 Humanized Monoclonal Antibody Injection" an
Learn moreThe 2023 Bio-Europe, a major European biotechnology exhibition, was grandly held in Munich, Germany from November 6th to 8th. The conference themes included global trends in biomedicine and innovative
Learn moreOn September 29, 2023, Mabgeek Biotech announced that its humanized monoclonal antibody injection ta
Learn moreOn June 29, 2023, Mabgeek Biotech announced that its MG-K10 (comekibart) humanized monoclonal antibody injection for the treatment of patients with moderate to severe atopic dermatitis has achieved th
Learn moreOn June 15, 2023, the clinical trial application for the antibody drug "MG-013 Humanized Monoclonal Antibody Injection" submitted by Mabgeek Biotech was accepted. It is intended to be developed for th
Learn moreShanghai Mabgeek Biotech Co., Ltd. (hereinafter referred to as "Mabgeek Biotech") is a clinical-stage innovative drug research and development company. The company announced that its independent
Learn moreOn February 28, 2023, Heze Modern Pharmaceutical Port and Mabgeek Biotech signed a strategic cooperation framework agreement in Shanghai. Present at the signing ceremony were Zhang Xinwen, Vice Chairm
Learn moreOn October 25, 2022, Shanghai Mabgeek Biotech Co., Ltd. (Mabgeek, hereinafter referred to as "Mabgee
Learn moreThe second antibody drug submitted by Mabgeek Biotech, "MG-ZG122 Humanized Monoclonal Antibody Injec
Learn moreOn May 20, 2022, the clinical trial application for the second antibody drug "MG-ZG122 Humanized Monoclonal Antibody Injection" submitted by Mabgeek Biotech was accepted. Compared with the currently m
Learn moreChime Biologics Announces a Strategic Collaboration with Mabgeek to Accelerate the development of Mo
Learn moreAt the beginning of the New Year 2022,Mabgeek Biotech organized a two-day team-building activity in
Learn moreThe 2021 Gusu Dialogue, themed "Innovation · Future · Globalization", aims to focus on hot topics in the pharmaceutical industry, pay attention to cutting-edge innovations, and gather industrial wisdo
Learn moreOn April 24, 2019, in the fourth month of the year, with grass growing and orioles flying, all things coming back to life, it was the perfect time for an outing and enjoying the spring scenery. Taking
Learn moreAll Rights Reserved by HUNAN MABGEEK BIOTECH CO., LTD © 2018-2024 mabge.com